A PYMNTS Company

Becton Dickinson Heads To Trial In Catheter Antitrust Case

By  |  May 6, 2021

Becton Dickinson subsidiary CR Bard must face trial on claims that it’s trying to corner the market for certain blood vessel catheters by leveraging its monopoly on an electronic system for locating them within the body, a federal judge in Syracuse, New York, ruled.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Judge Brenda K. Sannes denied dueling motions by Bard and AngioDynamics, the rival device maker leading the lawsuit, refusing either to throw out the antitrust case or impose liability without the benefit of a trial in the US District Court for the Northern District of New York.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Albany, N.Y.-based Angiodynamic’s lawsuit claims that Bard has a dominant position in the tip location system market and will only sell the stylet necessary to operate its tip location systems preloaded in its PICCs, not separately which would allow any type of PICC to be used with the tip location systems.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.